

Katja Strohfeldt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2480057/publications.pdf>

Version: 2024-02-01

32
papers

1,641
citations

257101

24
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

1056
citing authors

#	ARTICLE	IF	CITATIONS
1	The power of the virtual client " using problem-based learning as a tool for integration in a pharmaceutical sciences laboratory course. Higher Education Pedagogies, 2019, 4, 462-475.	2.1	0
2	Analysis of Three Epoetin Alpha Products by LC and LC-MS Indicates Differences in Glycosylation Critical Quality Attributes, Including Sialic Acid Content. Analytical Chemistry, 2017, 89, 6455-6462.	3.2	25
3	Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy. Scientific Reports, 2017, 7, 5738.	1.6	41
4	Using Problem-Based Learning in a Chemistry Practical Class for Pharmacy Students and Engaging Them with Feedback. American Journal of Pharmaceutical Education, 2015, 79, 141.	0.7	21
5	Titanocene anticancer complexes and their binding mode of action to human serum albumin: A computational study. Metallomics, 2011, 3, 152.	1.0	18
6	A Model for Self-Directed Problem-Based Learning for Renal Therapeutics. American Journal of Pharmaceutical Education, 2010, 74, 173.	0.7	25
7	Silyl-Modified Analogues of Tritylpyrrolidine: Synthesis and Applications in Asymmetric Organocatalysis. Chemistry - A European Journal, 2010, 16, 12553-12558.	1.7	37
8	Proliferative and anti-proliferative effects of titanium- and iron-based metallocene anti-cancer drugs. Journal of Organometallic Chemistry, 2009, 694, 874-879.	0.8	43
9	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and aryl-substituted titanocene anti-cancer agents. European Journal of Medicinal Chemistry, 2008, 43, 122-128.	2.6	30
10	Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chemical Society Reviews, 2008, 37, 1174.	18.7	310
11	Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice. Letters in Drug Design and Discovery, 2008, 5, 141-144.	0.4	24
12	Antiproliferative activity of Titanocene Y against tumor colony-forming units. Anti-Cancer Drugs, 2007, 18, 317-321.	0.7	46
13	Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice. Anti-Cancer Drugs, 2007, 18, 311-315.	0.7	50
14	The synthesis and cytotoxic evaluation of a series of benzodioxole substituted titanocenes. Applied Organometallic Chemistry, 2007, 21, 57-65.	1.7	27
15	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and heteroaryl-substituted titanocene anti-cancer drugs. Journal of Organometallic Chemistry, 2007, 692, 2153-2159.	0.8	45
16	Synthesis and cytotoxicity studies of new dimethylamino-functionalised and indolyl-substituted titanocene anti-cancer drugs. Transition Metal Chemistry, 2007, 32, 434-441.	0.7	18
17	Proliferative and antiproliferative effects in substituted titanocene anticancer drugs. Transition Metal Chemistry, 2007, 32, 971-980.	0.7	4
18	Crystal Structures of [PhLi(THF)-sparteine] ₂ , [PhOLi(THF)-sparteine] ₂ , and the Mixed Aggregate [PhLi·PhOLi·2(THF)-sparteine]. Organometallics, 2006, 25, 41-44.	1.1	45

#	ARTICLE	IF	CITATIONS
19	Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice. <i>Anti-Cancer Drugs</i> , 2006, 17, 333-336.	0.7	69
20	Diheteroarylmethyl substituted titanocenes: A novel class of possible anti-cancer drugs. <i>Inorganica Chimica Acta</i> , 2006, 359, 3969-3975.	1.2	30
21	Diarylmethyl substituted titanocenes: Promising anti-cancer drugs. <i>Polyhedron</i> , 2006, 25, 2101-2108.	1.0	32
22	Heteroaryl substituted titanocenes as potential anti-cancer drugs. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 1479-1486.	1.5	40
23	Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour. <i>European Journal of Pharmacology</i> , 2006, 534, 264-270.	1.7	46
24	Glycol Methyl Ether and Glycol Amine Substituted Titanocenes as Antitumor Agents. <i>European Journal of Inorganic Chemistry</i> , 2006, 2006, 4621-4628.	1.0	23
25	Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming units. <i>Anti-Cancer Drugs</i> , 2005, 16, 1071-1073.	0.7	45
26	In-vitro anti-tumor activity studies of bridged and unbridged benzyl-substituted titanocenes. <i>Anti-Cancer Drugs</i> , 2005, 16, 1091-1098.	0.7	105
27	A trimethoxyphenyl substituted ansa-titanocene: A possible anti-cancer drug. <i>Polyhedron</i> , 2005, 24, 1250-1255.	1.0	40
28	Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. <i>Applied Organometallic Chemistry</i> , 2005, 19, 293-300.	1.7	68
29	Novel benzyl substituted titanocene anti-cancer drugs. <i>Journal of Organometallic Chemistry</i> , 2005, 690, 4537-4544.	0.8	118
30	Crystal Structures of (+)-Sparteine Surrogate Adducts of Methyllithium and Phenyllithium. <i>Organometallics</i> , 2004, 23, 5389-5391.	1.1	63
31	[tBuLi⋯(âˆ“)-Sparteine]: Molecular Structure of the First Monomeric Butyllithium Compound. <i>Angewandte Chemie - International Edition</i> , 2003, 42, 4531-4533.	7.2	73
32	The Crystal Structures of the Chiral Alkyl lithium Bases [n-BuLi⋯(âˆ“)-Sparteine]2 and [Et2O⋯(i-PrLi)2⋯(âˆ“)-Sparteine]. <i>Journal of the American Chemical Society</i> , 2003, 125, 13672-13673.	6.6	79